Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC") as the sole agent and bookrunner on a commercially re
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-11-24 7:00 AM EST | Theralase Technologies Inc.
Skye Bioscience to Participate in Upcoming Investment Conferences
San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences: Citi Global Healthcare Conference (Miami) 1x1 meetings: Dec. 2 Evercore Annual Healthcare Conference (Coral Gables) Fireside Chat: Dec. 3, 12:55 pm
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-11-24 7:00 AM EST | Skye Bioscience, Inc.
Defence Therapeutics Announces Convertible Debenture Conversion
Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), announces that the holders of the Corporation's 8% convertible debentures issued on November 16, 2024 (the "Debentures") have converted all of the principal amount and the accrued interests thereof into an aggregate number of 2,607,600 common
Biotechnology, Pharmaceuticals, Health
2025-11-21 6:03 PM EST | Defence Therapeutics Inc.
Shuttle Pharmaceuticals Acquires AI Health Platform
Rockville, Maryland--(Newsfile Corp. - November 21, 2025) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle" or the "Company") today announced that it has closed the acquisition of the assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai ("Molecule"), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies. Under the terms of the agreement, 1563868 B.C. Ltd., a wholly owned subsidiary of Shuttle, ac
2025-11-21 9:30 AM EST | Shuttle Pharmaceuticals Holdings Inc.
PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its news release of earlier today, the Company wishes to clarify that shareholders of record of November 24, 2025 will be issued new common shares of PreveCeutical and 0.02 of one share of BioGene Therapeutics Inc. About PreveCeutical PreveCeutical is a heal
Biotechnology, Pharmaceuticals, Health
2025-11-20 12:26 PM EST | PreveCeutical Medical Inc.
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
Calgary, Alberta--(Newsfile Corp. - November 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option patients suffering from pain, angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce Dr. William R. Shankle, MS,
Biotechnology, Pharmaceuticals, Health
2025-11-20 9:00 AM EST | Hemostemix Inc.
Former US Congressman Dr. Brad Wenstrup Joins Maxwell Board
Austin, Texas--(Newsfile Corp. - November 20, 2025) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Dr. Brad Wenstrup to its Board of Directors. This appointment adds a key national biodefense expert to Maxwell's board.
Biotechnology, Pharmaceuticals
2025-11-20 9:00 AM EST | Maxwell Biosciences, Inc.
Conexeu Sciences Signals a Major Breakthrough in 'Personalized Human Tissue Creation'
Reno, Nevada--(Newsfile Corp. - November 20, 2025) - Conexeu Sciences Inc. ("Conexeu" or the "Company"), a biotechnology innovator redefining regenerative medicine through a next-generation collagen-based platform, is pleased to announce that it has achieved a defining milestone in regenerative medicine with the first ever 3D-printed structures made entirely from its patented, functional extracellular matrix (ECM). Using its patented CXU™ platform, the Company has printed bovine-derived
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-20 9:00 AM EST | Conexeu Sciences Inc.
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention to make a normal course issuer bid, or NCIB, for its common shares (TSX: MDP). Under the NCIB, Medexus may purchase for cancellation up to 2,983,650 common shares, representing approximately 10% of the public float as defined under TSX rules. As of November 12, 2025, 32
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-20 7:30 AM EST | Medexus Pharmaceuticals Inc.
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025 and October 20, 2025, the Company announces that it will be completing
Biotechnology, Pharmaceuticals, Health
2025-11-20 7:00 AM EST | PreveCeutical Medical Inc.
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has completed its previously announced non-brokered private placement (the "Non-Brokered Unit Offering") to certain institutional investors and other acc
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-19 4:26 PM EST | NervGen Pharma Corp.
Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology
Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce a major step forward in the fight against cancer that goes beyond the ADCs current limitations. Following successful presentations and meetings at the World ADC Conference in San Diego with ADC companies as well as
Biotechnology, Pharmaceuticals, Health
2025-11-19 3:15 AM EST | Defence Therapeutics Inc.
Hemostemix Closes CDN$280,594 Private Placement
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida
Biotechnology, Pharmaceuticals, Health
2025-11-18 5:08 PM EST | Hemostemix Inc.
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it is conducting a non-brokered private placement (the "Non-Brokered Unit Offering") to certain institutional investors and other accredited inves
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-18 4:42 PM EST | NervGen Pharma Corp.
Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care Conference from December 11-14, 2025 in Key West, Florida. The company will highlight its world-leading angiogenic cell therapy, ACP-01, which regenerates circulation, heals ulcers, alleviates pain, and improves quality of life for patients with advanced wound care needs including Peri
Biotechnology, Pharmaceuticals, Health
2025-11-18 11:30 AM EST | Hemostemix Inc.
XPOVIO(R) (selinexor) Now Funded in Quebec
Oakville, Ontario--(Newsfile Corp. - November 18, 2025) - FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is publicly funded in Quebec for the treatment of multiple myeloma as of November 6, 2025. Please see the following link for full funding criteria: Liste des médicaments fournis en établissement | Régie de l'assurance maladie du Québec (RAMQ) (https://www.ramq.gouv.qc.ca/fr/a-
Healthcare and Hospitals, Pharmaceuticals
2025-11-18 9:31 AM EST | FORUS Therapeutics Inc.
XPOVIO(R) (sélinexor) est maintenant financé au Québec
Oakville, Ontario--(Newsfile Corp. - 18 novembre 2025) - FORUS Therapeutics a le plaisir d'annoncer que XPOVIO® (sélinexor) bénéficie d'un financement public au Québec pour le traitement du myélome multiple depuis le 6 novembre 2025. Veuillez consulter le lien suivant pour connaître tous les critères de financement : Liste des médicaments fournis en établissement | Régie de l'assurance maladie du Québec (RAMQ) (http
Healthcare and Hospitals, Pharmaceuticals
2025-11-18 9:00 AM EST | FORUS Therapeutics Inc.
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of proprietary small-molecule d
Biotechnology, Pharmaceuticals
2025-11-18 7:30 AM EST | InMed Pharmaceuticals
TempraMed Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares are now listed and trading on the Frankfurt Stock Exchange under the trading symbol "9DY." The Company is also pleased to announce it has retained bullVestor Medien GmbH ("bullVestor") to provide certain marketing services for a period of 3 months, commencing on November 18, 2025
Technology, Biotechnology, Pharmaceuticals, Health
2025-11-18 7:00 AM EST | TempraMed Technologies Ltd
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
King of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation highlighting INTASYL® siRNA Drug Technology will be held at the Advanced Therapies USA 2025 Congress in Philadelphia, PA at the Pennsylvania Convention
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-17 8:45 AM EST | Phio Pharmaceuticals Corp.